BCEL's logo.
Ticker Symbol: BCEL

Atreca Inc - Class A

$5.19 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001532346

Company Profile

atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 450 East Jamie Court
CEO: John Orwin
Tags:
  • Miscellaneous Commercial Services
  • Commercial Services
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.27
Change: -$0.09 ( -26.40%)
Days Range: $0.26 - $0.34
Beta: 1.49
52wk. High: $2.04
52wk. Low: $0.20
Ytd. Change -92.55%
50 Day Moving Average: $0.30
200 Day Moving Average: $0.76
Shares Outstanding: 32580220

Valuation

Market Cap: 882.9M
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A